Your participation in this survey is crucial in helping us develop the evidence and resources to further the field of Immunization Economics. This survey should take around 20 minutes to complete. Thank you very much for your support. Take the survey here
New analyses revealed costs distribution across budget categories and programmatic activities, and investigated variation of the cost structure by country and site characteristics. See more here
Recent workshop discussed the state of research on the broader social and economic impacts of vaccination (BSEIV), including ongoing and prospective research. Access summary and presentation materials here
Robert Steinglass, Director of the Immunization Center at JSI, delivered a keynote address during the recent workshop: Innovative Approaches to Widening and Deepening Research on the Value of Vaccination. See more here
ICAN research teams from Indonesia, Tanzania, and Vietnam discussed research questions and study designs, which aims to build capacity around generation and use of cost evidence to work toward sustainable immunization financing. See more here
Focused on capacity building in applied vaccine economics, cost-effectiveness and finance, TVEE targets audience who are current decision-makers in EPI programs, NiTAGs and partners in GAVI eligible countries. Read more here
This one and half day training workshop covers applied vaccine economics, finance and cost-effectiveness. This iHEA pre-congress workshop will take place in Boston, Friday July 7th; 13:30-17:00 and Saturday July 8th; 8:30-17:00. See more here
Researchers have identified vaccination benefits that should be incorporated into economic evaluations to reflect vaccination’s full value. The article discusses data sources, methods, and research questions to be explored. See more here
Tools, guidance and lessons learned from the PAHO ProVac Initiative’s capacity-building efforts to strengthen evidence-based immunization policy in Latin America and the Caribbean are now available. See more here
A new resource guide, Immunization Financing: A Resource Guide for Advocates, Policymakers, and Program Managers, provides practical advice through 26 briefs to assist countries looking to sustainably finance immunization. See more here
Include your papers, reports, presentations, policy documents, or data sets for a systematic review of published and grey literature on the delivery costs of immunization programs in low- and middle-income countries. See more here
Leading experts in the field of vaccination research convened on April 2016 to identify barriers impeding evaluations of the economic impact of immunization to help guide investments in this area. See workshop background and summary.
Accurate information on the cost and financing of national immunization programs can be lacking. Research and a new website are designed to help governments worldwide manage their immunization programs and plan for the future. See more here
Forty experts and policy makers reviewed the current evidence on immunization delivery costs and identified essential information needs, methodological issues, gaps in use of data, as well as priorities and future actions. Read report here
A recent issue of Health Affairs published the return on investment for vaccination in 94 low- and middle-income countries. Furthermore, an EPIC study finds that governments fund more than half of total immunization expenditures. See more here
This is the result of a new study, published in the journal Health Affairs. Projected vaccination rates of 94 low- and middle-income countries from 2011 to 2020 were used to determine the economic benefits. See more here
Vaccine Volume 33, Supplement 1, Pages A1-A254 (7 May 2015): Expanding the Evidence Base to Inform Vaccine Introduction: Program Costing and Cost-effectiveness Analyses. See more here
The recent issue published, among others, papers on the return on investment, and the share of government financing of immunization program. The briefing video, audio, agenda, and slides have been posted to Health Affair's website.
PAHO / WHO: Although new vaccines are more costly than traditional ones, they are overwhelmingly cost-effective and should continue to be considered a public health "best buy." See more here.
Performance, productivity and costs of immunization programs - evidence from the EPIC studies. This panel session focuses on the productivity and cost determinants of routine immunization programs. See more here.
The resource requirements for national immunizations have rapidly increased in the last decade with the introduction of costly new vaccines. In this context, accurate information on the cost and financing of national immunization programs is essential for strategic planning and program management activities of national ministries as well as for donors.
Despite the existence of tools such as the World Health Organization’s Comprehensive Multi-Year Planning Tool (CMYP) and the Joint Reporting Form, high-quality information on costs, expenditures, and funding flows are generally lacking. Where such information exists, it is not easily comparable across settings, and it is rarely used to examine productive efficiency.
To address this gap, the Bill & Melinda Gates Foundation provided financing for EPIC--a coordinated set of immunization costing and financing studies in 2012-2014 in six countries (Benin Ghana Uganda Zambia Moldova and Honduras). These studies collected data at central, subnational, and facility-level and were notable for their rigor in terms of sample design and comprehensiveness of resource use measurement.